ArticleBMC veterinary research2025
Development and validation of prognostic nomogram for overall survival in canine multicentric lymphoma: a retrospective study.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate prognostic nomogram for predicting 3-month, 6-month, and 12-month overall survival in canine multicentric lymphoma. A total of 163 cases from January 2019 to December 2024 were used as a training set, and 50 cases from January 2017 to January 2019 served as a validation set. Predictors were identified using LASSO regression and univariate/multivariate Cox regression analyses, leading to the development of the nomogram: ATRAS2, incorporating age, red blood cell count at diagnosis, changes in red blood cell count after chemotherapy, and albumin-to-globulin ratio. Internal validation showed areas under the receiver operating characteristic curve for ATRAS2 of 0.991, 0.932, and 0.919 for 3-month, 6-month, and 1-year overall survival, respectively. Temporal validation yielded concordance indices of 0.708, 0.701 and 0.783 for 3-month, 6-month, and 1-year overall survival with calibration plots demonstrating strong agreement between predicted and observed overall survival. Decision curve analysis further confirmed the clinical utility of both models for 3-month, 6-month, and 12-month overall survival. The nomogram offers a tool for personalized survival evaluation of canine multicentric lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.